{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:25:45Z","timestamp":1778653545300,"version":"3.51.4"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Red Espa\u00f1ola de Investigaci\u00f3n del SIDA","award":["RD16\/0025\/0007"],"award-info":[{"award-number":["RD16\/0025\/0007"]}]},{"name":"Plan Nacional R\u2009+\u2009D+I"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The combination of boosted darunavir plus rilpivirine, once daily, could be a convenient, effective and well-tolerated two-drug regimen to achieve HIV suppression in HIV-infected patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Multicentre, retrospective cohort study in nine hospitals in Spain. All HIV-infected subjects starting boosted darunavir plus rilpivirine were included, irrespective of their viral load (VL). The primary objective was the percentage of patients with VL &amp;lt;50\u2005copies\/mL at 48\u2009weeks. Secondary objectives included changes in CD4+ cell count, lipid profile and renal function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighty-one of 84 patients reached Week 48. Fifty-nine (70.2%) patients had VL &amp;lt;50\u2005copies\/mL at baseline and the rest had a median VL of 202 (IQR 98\u2013340) copies\/mL. Subjects had a median of 21\u2009years of infection with six prior regimens. The main reasons for starting boosted darunavir plus rilpivirine were simplification (44%), kidney or bone toxicity (28.6%) and virological failure (17.9%). Historical genotypes from 47 patients showed 41 (87.2%) patients with NRTI RAMs, 21 (44.7%) with NNRTI RAMs, 12 (25.5%) with primary PI RAMs and 7 (14.9%) with integrase strand transfer inhibitor (INSTI) RAMs. One patient had low-level resistance to boosted darunavir and five patients had some resistance to rilpivirine. At 48\u2009weeks, 71 (87.7%) patients had VL &amp;lt;50\u2005copies\/mL. According to undetectable or detectable baseline VL, effectiveness was 91.1% or 80%, respectively. There were four virological failures with no emergence of new RAMs. Three of these patients resuppressed viraemia while maintaining the same regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The combination of boosted darunavir plus rilpivirine has shown good effectiveness and tolerability in this cohort of pretreated patients with a long-lasting HIV infection, exposure to multiple antiretroviral regimens and prior HIV resistance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa072","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T12:09:47Z","timestamp":1581422987000},"page":"1955-1960","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7187-0367","authenticated-orcid":false,"given":"Jordi","family":"Navarro","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Vall d\u2019Hebron Research Institute, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gonz\u00e1lez-Cord\u00f3n","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital Cl\u00ednic - IDIBAPS, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7639-8591","authenticated-orcid":false,"given":"Jos\u00e9 Lu\u00eds","family":"Casado","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital Ramon y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3501-8529","authenticated-orcid":false,"given":"Jose I","family":"Bernardino","sequence":"first","affiliation":[{"name":"HIV Unit, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Domingo","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin","family":"Portilla","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital General Universitario de Alicante, Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep Maria","family":"Llibre","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Colomer","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Hospital de Santa Caterina, Salt, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rial-Crestelo","sequence":"first","affiliation":[{"name":"HIV Unit, Hospital 12 de Octubre, imas12, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8553-6995","authenticated-orcid":false,"given":"Pilar","family":"Vizcarra","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital Ramon y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e0","family":"Curran","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Vall d\u2019Hebron Research Institute, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Mart\u00ednez","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital Cl\u00ednic - IDIBAPS, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Ribera","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Vall d\u2019Hebron Research Institute, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"2020061904533961300_dkaa072-B1"},{"key":"2020061904533961300_dkaa072-B2"},{"key":"2020061904533961300_dkaa072-B3","year":"2019"},{"key":"2020061904533961300_dkaa072-B4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jac\/dkw379","article-title":"Simplification to dual therapy (atazanavir\/ritonavir + lamivudine) versus standard triple therapy [atazanavir\/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study","volume":"72","author":"Perez-Molina","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020061904533961300_dkaa072-B5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(15)00096-1","article-title":"Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial","volume":"15","author":"Arribas","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2020061904533961300_dkaa072-B6","first-page":"191","article-title":"Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppression","volume":"316","author":"Pulido","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020061904533961300_dkaa072-B7","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1093\/jac\/dky299","article-title":"Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717","volume":"73","author":"Perez-Molina","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020061904533961300_dkaa072-B8","doi-asserted-by":"crossref","first-page":"21678.","DOI":"10.7448\/IAS.20.01.21678","article-title":"Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study","volume":"20","author":"Cahn","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"2020061904533961300_dkaa072-B9","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/jac\/dky564","article-title":"Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA &lt;500000 copies\/mL: week 48 outcomes from ACTG 5353","volume":"74","author":"Nyaku","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020061904533961300_dkaa072-B10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2020061904533961300_dkaa072-B11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dky467","article-title":"Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)","volume":"74","author":"Joly","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020061904533961300_dkaa072-B12","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/cid\/cix1131","article-title":"Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020061904533961300_dkaa072-B13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/phar.2227","article-title":"Effectiveness of once\/day dolutegravir plus boosted darunavir as a switch strategy in heavily treated patients with human immunodeficiency virus","volume":"39","author":"Navarro","year":"2019","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"2020061904533961300_dkaa072-B14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3851\/IMP3095","article-title":"Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort","volume":"22","author":"Capetti","year":"2016","journal-title":"Antivir Ther"},{"key":"2020061904533961300_dkaa072-B15","doi-asserted-by":"crossref","first-page":"e0210476.","DOI":"10.1371\/journal.pone.0210476","article-title":"Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients","volume":"14","author":"Jab\u0142onowska","year":"2019","journal-title":"PLoS One"},{"key":"2020061904533961300_dkaa072-B16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3947\/ic.2018.50.3.252","article-title":"Effectiveness, safety, and tolerability of a switch to dual therapy with dolutegravir plus cobicistat-boosted darunavir in treatment-experienced patients with human immunodeficiency virus","volume":"50","author":"Lee","year":"2018","journal-title":"Infect Chemother"},{"key":"2020061904533961300_dkaa072-B17","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/QAD.0000000000000169","article-title":"Week 48 results from a randomized clinical trial of rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate vs. efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults","volume":"28","author":"Cohen","year":"2014","journal-title":"AIDS"},{"key":"2020061904533961300_dkaa072-B18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/QAD.0000000000000911","article-title":"Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study","volume":"30","author":"van Lunzen","year":"2016","journal-title":"AIDS"},{"key":"2020061904533961300_dkaa072-B19","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S2352-3018(17)30032-2","article-title":"Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study","volume":"4","author":"DeJesus","year":"2017","journal-title":"Lancet HIV"},{"key":"2020061904533961300_dkaa072-B20","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/S2352-3018(17)30031-0","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study","volume":"4","author":"Orkin","year":"2017","journal-title":"Lancet HIV"},{"key":"2020061904533961300_dkaa072-B21","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/jac\/dky175","article-title":"Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine\/emtricitabine\/tenofovir due to intolerance to previous combination ART: the PRO-STR study","volume":"73","author":"Ocampo","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020061904533961300_dkaa072-B22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/QAD.0000000000000087","article-title":"Simplification to rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants","volume":"28","author":"Palella","year":"2014","journal-title":"AIDS"},{"key":"2020061904533961300_dkaa072-B23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"2020061904533961300_dkaa072-B24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.24875\/AIDSRev.M18000026","article-title":"New dual combination of dolutegravir-rilpivirine for switching to maintenance antiretroviral therapy","volume":"20","author":"Ribera","year":"2019","journal-title":"AIDS Rev"},{"key":"2020061904533961300_dkaa072-B25","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3018(17)30179-0","article-title":"Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a Phase 3, randomised, non-inferiority trial","volume":"5","author":"Orkin","year":"2018","journal-title":"Lancet HIV"},{"key":"2020061904533961300_dkaa072-B26","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/QAD.0000000000001817","article-title":"A week-48 randomized phase-3 trial of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-naive HIV-1 patients","volume":"32","author":"Eron","year":"2018","journal-title":"AIDS"},{"key":"2020061904533961300_dkaa072-B27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/157016212799937218","article-title":"Week 96 efficacy, virology and safety of darunavir\/r versus lopinavir\/r in treatment-experienced patients in TITAN","volume":"10","author":"B\u00e1nhegyi","year":"2012","journal-title":"Curr HIV Res"},{"key":"2020061904533961300_dkaa072-B28","first-page":"111","article-title":"2019 update of the drug resistance mutations in HIV-1","volume":"27","author":"Wensing","year":"2019","journal-title":"Top Antivir Med"},{"key":"2020061904533961300_dkaa072-B29","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2352-3018(17)30069-3","article-title":"Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286\/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial","volume":"4","author":"Ciaffi","year":"2017","journal-title":"Lancet HIV"},{"key":"2020061904533961300_dkaa072-B30","year":"2018"},{"key":"2020061904533961300_dkaa072-B31","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1089\/aid.2015.0331","article-title":"Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE study","volume":"32","author":"Lam","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020061904533961300_dkaa072-B32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/QAI.0000000000000966","article-title":"NRTI sparing therapy in virologically controlled HIV-1 infected subjects: results of a controlled, randomized trial (Probe","volume":"72","author":"Maggiolo","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020061904533961300_dkaa072-B33","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1177\/1060028018761600","article-title":"Dolutegravir plus rilpivirine as a switch option in cART-experienced patients: 96-week data","volume":"52","author":"Capetti","year":"2018","journal-title":"Ann Pharmacother"},{"key":"2020061904533961300_dkaa072-B34","doi-asserted-by":"crossref","first-page":"232595821876084.","DOI":"10.1177\/2325958218760847","article-title":"Safety and efficacy of dolutegravir plus rilpivirine in treatment-experienced HIV-infected patients: the DORIVIR study","volume":"17","author":"Palacios","year":"2018","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2020061904533961300_dkaa072-B35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/hiv.12386","article-title":"Week 96 efficacy and safety of darunavir\/ritonavir monotherapy vs. darunavir\/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial","volume":"18","author":"Girard","year":"2017","journal-title":"HIV Med"},{"key":"2020061904533961300_dkaa072-B36","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/jac\/dky093","article-title":"Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial","volume":"73","author":"Blanco","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020061904533961300_dkaa072-B37","author":"Gathe"},{"key":"2020061904533961300_dkaa072-B38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/15284336.2017.1408928","article-title":"Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir\/ritonavir in treatment-na\u00efve HIV-1-infected individuals","volume":"19","author":"Jackson","year":"2018","journal-title":"HIV Clin Trials"},{"key":"2020061904533961300_dkaa072-B39","author":"Ma"},{"key":"2020061904533961300_dkaa072-B40","author":"van Heeswijk"},{"key":"2020061904533961300_dkaa072-B41","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1370\/afm.2315","article-title":"Legacy drug-prescribing patterns in primary care","volume":"16","author":"Mangin","year":"2018","journal-title":"Ann Fam Med"},{"key":"2020061904533961300_dkaa072-B42","doi-asserted-by":"crossref","first-page":"3.","DOI":"10.1186\/s12872-016-0453-6","article-title":"Is the concomitant use of clopidogrel and proton pump inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012\u20132016","volume":"17","author":"Bundhun","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"2020061904533961300_dkaa072-B43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1060028016673859","article-title":"Association between proton pump inhibitors and microscopic colitis","volume":"51","author":"Law","year":"2017","journal-title":"Ann Pharmacother"},{"key":"2020061904533961300_dkaa072-B44","doi-asserted-by":"crossref","first-page":"1571.","DOI":"10.3390\/ijerph16091571","article-title":"Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved","volume":"16","author":"Thong","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"2020061904533961300_dkaa072-B45","first-page":"87","article-title":"Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine","volume":"15","author":"Crauwels","journal-title":"AIDS Rev"},{"key":"2020061904533961300_dkaa072-B46","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/cid\/civ296","article-title":"The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial","volume":"61","author":"Santos","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020061904533961300_dkaa072-B47","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/hiv.12630","article-title":"Switching to abacavir versus use of a nucleoside-sparing dual regimen for HIV-infected patients with tenofovir-associated renal toxicity","volume":"19","author":"Casado","year":"2018","journal-title":"HIV Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/7\/1955\/33405115\/dkaa072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/7\/1955\/33405115\/dkaa072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T08:53:59Z","timestamp":1592556839000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/7\/1955\/5781883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,3,5]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa072","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,3,5]]}}}